Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Senti
I can't see what you are replying to but it sounds like you are talking about Ctrl+F or Command+F
Or perhaps something of this sort:
https://discussions.apple.com/thread/4325736?tstart=0
I just saw you and soonerx discussed later. No worries, see ya.
Chris-
I know Sarepta very well. Probably my #2.
There was a 1:6 reverse split in there in July 2012.
Accomodating for that your numbers should be more like this:
6/2012 was $3.70
10/2012 peaked at $44.93
Still a 1115% return but not 5432% like your numbers imply.
and, we wait...
Anyone listening to anything on seekingalpha deserves to lose their shirt...no offense
The same chatter amongst physicians that you mention happened quite a bit with Nuplazid just before approval.
There will be one more dilution before significant news. If the next dilution is $0.34 or higher, that is a buy signal based on the foundation it formed December 20 - January 9.
Bye
Shocker
Wrong pfort. Refer to post 98212 and especially the hyperlink. 13F filers don't need to report NWBO anymore. You don't know whether they sold or are still holding it. The mandatory reporting has gone to zero.
There are only 3M shares outstanding. Everything is over-exaggerated. It will probably be down 30% tomorrow.
They had a 1:40 reverse split 2 months ago. I like where I am instead.
They are both just stating the top from 7/23/2015. It's not a coincidence of value placed on anything.
Anyone worried about this, please see post 98212. NWBO is no longer considered a reportable security by the SEC for 13Fs. All of these companies are following 13F filing protocol and when their holdings get uploaded to Edgar, NWBO is set to zero because the SEC no longer cares whether people hold it due to the OTC move. I personally hold shares at my company and we are now stating ZERO.
Absolutely there are
No, pre-market bid/ask means nothing OTC unless both are very different from the last close in the same direction. In today's case it was just the Ax, aka Knight, had not posted yet.
Hahahahaha. Yes, you probably should.
Can somebody explain what Dr. Cobb says at 1:38:45, basically the closing remark of the DCVax conversation?
I respectfully disagree with you guys on this issue. Diluting down at these levels destroys the chance of gains exponentially. I am talking about the big scores. The chances are diminishing rapidly. My opinion only, which won't change.
thanks hwy
I want it stated in an official filing, even though I believe what Liau said. The halt is over, it's time to support the stock.
CVI posted a 13G. They have sold shares
https://www.sec.gov/Archives/edgar/data/1072379/000110465917008035/a17-3953_24sc13ga.htm
Your first paragraph reminded me of a tweet I came across earlier today accompanied by an article:
@ASCO wants cancer drugs to extend survival by 2.5 mos. Only 1 in 5 meet that goal, https://t.co/xbNMXA4wha
— Liz Szabo (@LizSzabo) February 9, 2017
No news or filings today on bloomberg. It looked like a BS move from 0.46 to 0.43 on level 2 to me. Nite left the ask and it quickly came back up. They're back on the ask now.
Washington Business Journal:
http://www.bizjournals.com/washington/news/2017/02/09/fda-lifts-hold-on-northwest-bio-s-brain-cancer.html?ana=bbg
Nothing new or exciting but published today.
Bohsie, glad you are here. You bring a lot of value.
Financials are not strong. Wow. Thanks for the newsflash. This is a pre revenue biotech not f'ing Apple.
You aren't
Yep, as they should now that the halt is gone.
New 8k:
Item 8.01. Other Events.
Northwest Biotherapeutics, Inc. (the “Company”) has received a number of
shareholder inquiries asking for clarification whether the 331 patients
enrolled in its Phase III DCVax®-L Trial includes the 32 patients in a
Pseudo-Progressor arm or those 32 patients are in addition to the 331 patients
enrolled.
The Company is clarifying that the 32 patients in the Pseudo-Progressor Arm
are in addition to the 331 patients enrolled in the Main Arm of the Trial and
are not included in the 331. The Company notes that there are 90 patients in
other separate arms of the Trial in addition to the 331 patients in the Main
Arm, making a total of 421 patients. The 90 patients include the 32 patients
in the Pseudo-Progressor Arm, 55 patients in the Information Arm, and 3
patients who were enrolled at the very beginning of the Trial when it was
randomized but not yet blinded. The Trial was blinded after those initial
patients were enrolled. In addition to these 421 patients, the Company has
treated a substantial number of patients on a compassionate basis under an
Expanded Access Protocol.
It's on the clinical trial site: NCT00045968
Canada, Quebec
Montreal Neurological Institute, McGill University
Montreal, Quebec, Canada, H3A 2B4
CHUS - Hôpital Fleurimont
Sherbrooke, Quebec, Canada, J1H 5N4
Maybe they got that manor via funds NWBO funneled to them, you know since koman is over on "investors village idiots" saying the FDA is in cahoots to scam investors now too on a futile trial.
You need to look at his replies to tweets
That could be. I was going off bloomberg's information which is wrong sometimes. Bloomberg was telling me they had 4.9M shares on 12/29, I'll have to go back and check the older filing.
edit: yes it looks like they did. I pulled the older filing and bloomberg had bad information in the Holders section which is not uncommon. I'll have my older post removed.
Agreed. If this was at all about manufacturing, it's not an issue anymore.
NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached 2017-02-06 14:30:03.874 GMT
Process Now Moving Forward Toward Data Lock
PR Newswire
BETHESDA, Md., Feb. 6, 2017
BETHESDA, Md., Feb. 6, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:
NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Company's Phase III trial of DCVax®-L for Glioblastoma multiforme ("GBM") brain cancer (the "Trial"). The Company announced that the partial clinical hold on the Trial has been lifted by the FDA, and that the Trial has accumulated a sufficient number of events toward the progression-free survival ("PFS") endpoint, but not yet for the overall survival ("OS") endpoint.
The Company remains blinded to all Trial data, and is only receiving and reporting updates on a blinded basis.
On February 3, the FDA lifted the partial clinical hold which had been in place on the Trial. As previously reported, the Company has been in an ongoing dialog with regulators. The dialog culminated in the FDA lifting the partial hold. As previously announced by the Company, and as the Company also informed the FDA, the Company has closed enrollment and is not going to enroll the last 17 of the planned 348 patients.
There are 331 patients enrolled in the Trial. The Trial endpoints involve thresholds of 248 "events" for PFS and 233 "events" for OS. PFS events are primarily tumor progression (i.e., recurrence), although they can occasionally be patient deaths which occur without prior evidence of tumor recurrence. OS events are patient deaths. The PFS and OS events are continuing to accumulate as the Trial continues. The PFS events have surpassed the 248-event threshold, but the OS events have not yet reached the 233-event threshold. Based upon the pace of OS events during the last six to eight months, the Company's current anticipation is that it will be several months until the Trial reaches 233 OS events.
Dr. Linda Liau, Principal Investigator of the DCVax®-L Trial commented: "It is gratifying to have the hold removed from the Trial and exciting to see this Trial now moving towards completion, although of course the longer it takes for PFS and OS events to accrue, the better the patients in the Trial are doing."
The external parties managing the Trial are now moving forward with the process to reach data lock. In this process, all data from all of the treatment visits and follow up visits for all 331 patients in the Trial, must be subjected to quality control checking. The process involves in-person monitoring visits to all of the 80-plus sites in four countries to review the files onsite, as well as other documentary confirmation and checking of all MRI images. As such, it is a multi-month process. While this process is under way, OS and PFS events will continue to accumulate.
The Trial will reach data lock when the threshold events have been reached and the quality control checking has been completed for both the PFS and OS endpoints.
When data lock is reached, external statisticians and experts will make an independent analysis of the Trial data. The Company will remain blinded until data lock has been reached and the external data analysis has been completed.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion. The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.
The "market" doesn't know anything, as we will prove out with NWBO shortly.